Trial of NovoSeven® in Haemophilia - Joint Bleeds
Public ClinicalTrials.gov record NCT00108797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA®
Study identification
- NCT ID
- NCT00108797
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 42 participants
Conditions and interventions
Interventions
- Feiba VH Drug
- eptacog alfa (activated) Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 20 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2001
- Primary completion
- Jan 31, 2006
- Completion
- Jan 31, 2006
- Last update posted
- Jan 11, 2017
2001 – 2006
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Little Rock | Arkansas | 72202 | — |
| Novo Nordisk Investigational Site | Berkeley | California | 94704 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90027 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80010 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60612 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46260 | — |
| Novo Nordisk Investigational Site | Iowa City | Iowa | 52242 | — |
| Novo Nordisk Investigational Site | New Orleans | Louisiana | 70112 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02115 | — |
| Novo Nordisk Investigational Site | Detroit | Michigan | 48201 | — |
| Novo Nordisk Investigational Site | Minneapolis | Minnesota | 55404 | — |
| Novo Nordisk Investigational Site | New Brunswick | New Jersey | 08903 | — |
| Novo Nordisk Investigational Site | Newark | New Jersey | 07112 | — |
| Novo Nordisk Investigational Site | New York | New York | 10029-6574 | — |
| Novo Nordisk Investigational Site | Chapel Hill | North Carolina | 27599-7220 | — |
| Novo Nordisk Investigational Site | Cincinnati | Ohio | 45229 | — |
| Novo Nordisk Investigational Site | Hershey | Pennsylvania | 17033 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19104 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19134-1095 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00108797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2017 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00108797 live on ClinicalTrials.gov.